Cidara Therapeutics, Inc. (CDTX) |
|
1.16 -0.27 (-18.88%)
|
03-24 16:00 |
|
Open: |
1.43 |
Pre. Close: |
1.43 |
|
High:
|
1.42 |
Low:
|
1.1301 |
|
Volume:
|
8,049,661 |
Market Cap:
|
96(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:45 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 2.02  One year: 2.45 |
| Support: |
Support1: 1.13 Support2: 0.94 |
| Resistance: |
Resistance1: 1.72 Resistance2: 2.09 |
| Pivot: |
1.64 |
| Moving Average: |
MA(5): 1.64 MA(20): 1.64
MA(100): 1.07 MA(250): 0.81 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 29.4 %D(3): 52.6 |
| RSI: |
RSI(14): 37 |
| 52-week: |
High: 2.09 Low: 0.4 |
| Average Vol(K): |
3-Month: 3,129 (K) 10-Days: 6,153 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CDTX ] has closed below the lower bollinger band by 13.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 66.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.43 - 1.44 |
1.44 - 1.45 |
|
Low:
|
1.11 - 1.12 |
1.12 - 1.13 |
|
Close:
|
1.15 - 1.16 |
1.16 - 1.17 |
|
Company Description |
|
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. |
Headline News |
Thu, 23 Mar 2023
Cidara stock falls amid selloff in antifungal space (NASDAQ:CDTX) - Seeking Alpha
Thu, 23 Mar 2023
Cidara's Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment - Yahoo Life
Thu, 23 Mar 2023
Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today? - InvestorPlace
Thu, 23 Mar 2023
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Life
Thu, 23 Mar 2023
Coinbase Global, Cidara Therapeutics among premarket losers' pack - Seeking Alpha
Thu, 23 Mar 2023
Cidara Therapeutics: Q4 Earnings Snapshot - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
83 (M) |
| Shares Float |
55 (M) |
|
% Held by Insiders
|
9.6 (%) |
|
% Held by Institutions
|
33.6 (%) |
|
Shares Short
|
3,100 (K) |
|
Shares Short P.Month
|
1,750 (K) |
Stock Financials |
|
EPS
|
-0.55 |
|
EPS Est Next Qtl
|
-0.88 |
|
EPS Est This Year
|
-3.61 |
|
EPS Est Next Year
|
-3.29 |
|
Book Value (p.s.)
|
0.12 |
|
Profit Margin (%)
|
-54.3 |
|
Operating Margin (%)
|
-54.3 |
|
Return on Assets (ttm)
|
-35.2 |
|
Return on Equity (ttm)
|
-840.2 |
|
Qtrly Rev. Growth
|
475.7 |
|
Gross Profit (p.s.)
|
-0.29 |
|
Sales Per Share
|
0.74 |
|
EBITDA (p.s.)
|
-0.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-22 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-2.15 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
8.92 |
|
Price to Sales
|
1.56 |
|
Price to Cash Flow
|
-4.29 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
